Yissum - Research Development Company of the Hebrew University

Personalized Phage Therapy: A New Paradigm for Combating Antibiotic Resistance Infectious Disease

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Innovative Products and Technologies · Israel

Summary of the technology

A New Paradigm for Combating Infectious Disease in the Age of Antibiotic Resistance. Phage Therapy offers significant advantages: 1) Natural- Harnessing nature’s own enemy against bacteria 2) Smart kinetics
Phages grow with bacteria and disappear in its absence 3) Can be manipulated (unlike antibiotics) Engineered / evolutionary developed 4) Efficient against biofilm Chain reaction of the phages 5) Do not harm the microbiome Highly specific to the target pathogen. Hazan's approach for a Personalized Phage Therapy suggests an adaptive and dynamic cocktail of phages and antibiotics , that are specially tailored using AI and machine learning prediction. Hazan et.al. offer a constantly increasing “Bank” of phages.







Project ID : 43-2019-10746

Yissum - Research Development Company of the Hebrew University

Description of the technology

Nir-Paz Ran, Hadassah Medical Center

Background

The World Health Organization has announced antibiotic resistance is one of the biggest threats to global health, food security and development today. Up to 50% of infections in G7 countries may be resistant to first-line antibiotics

Patients with Antimicrobial Resistance (AMR) have 2-3 times higher mortality and risk of complications (e.g. local progression of disease and sepsis). Failure to address the problem of antibiotic resistance could result in 10 million deaths per year by 2050, surpassing cancer as the primary cause of deaths.

AMR treatments cost additional $10-40k per patient and an extra $23 billion for healthcare systems in Europe and North America alone. Accounting for extra healthcare costs, by 2050 up to $2.9 trillion of GDP could be lost across OECD countries due to AMR, at current resistance rates. It is estimated that the total economic output of antibiotic resistance will cost up to $100 trillion.

Why Phage Therapy?

In the past few years, FDA allows compassionate use of phage therapy; hence awareness is building quickly. As access and attention are growing- clinical trials under way.

Additional advantages:

  • Phage Therapy holds the potential to reverse this dangerous trend:
  • Natural - Harnessing nature’s own enemy against bacteria
  • Smart kinetics - Phages grow with bacteria and disappear in its absence
  • Can be manipulated (unlike antibiotics) - Engineered / evolutionary developed
  • Efficient against biofilm - Chain reaction of the phages
  • Do not harm the microbiome - Highly specific to the target pathogen

Our Innovation

We suggest a state of the art, dynamic and tailored approach for personalized phage therapy.

Our approach includes: Identification of phages from banks and new sources, Isolation using proprietary know-how and Machine Learning predictions. We offer Checkboard analyses for fighting bacteria resistance and Engineering the phages if needed as well as prediction of tailored phages and antibiotics cocktails for treatment.

We recently published our successful first phage therapy in Israel and one of the first ones in the world. The Patient suffered from severe osteomyelitis, and was prone to leg amputation. Following IV treatment with bacteriophages, the patient demonstrated full recovery after 10 days. Follow-up after 7 months has revealed no signs of relapse.

Opportunity

Our Vision: To be the leading international phage provider for therapy

Go-to-market plan: Strategic collaborations with hospitals + co-development agreements, consultancy

Cost per Case: $300K (Adaptive Phage Therapy)

Addressable Markets:

  • Clinics and hospitals globally, treating any antibiotic-resistant infection
  • Improvement of phage product pipelines
  • Agriculture chemical industry
  • Veterinary indications, primarily cattle

HUJI-HMC Phage Therapy Institute:

Collaboration of the Hebrew University oh Jerusalem and Hadassah Medical Center to establish an international Phage Therapy Center.Our center holds the potential to be the leading in the field, providing the full infrastructure required for personalized phage therapy: Diagnostic laboratory, manufacturing unit, unit of therapy within the hospital, alongside a bacteriophage research center.

Project manager

Shani Bullock
VP, Business Development, Healthcare

Project researchers

Ronen Hazan
HUJI, Faculty of Dental Medicine
Institute of Dental Sciences

Related keywords

  • Medicine, Human Health
  • Biology / Biotechnology
  • Genome Research
  • Micro- and Nanotechnology related to Biological sciences
  • Recombinant DNA
  • Monoclonal Antibodies and Hybridomas
  • Gene Splicing and Manufacturing Equipment
  • Other Genetic Engineering
  • Molecular design Market
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Toxicology Market
  • In vitro Testing, Trials Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Population genetics Market
  • Gene Expression, Proteom Research Market
  • Bioinformatics Market
  • Enzymology/Protein Engineering/Fermentation
  • Genetic Engineering Market
  • Diagnostic
  • Therapeutic
  • Other Medical/Health Related
  • Agro and Marine biotech
  • Anatomy, Pathology, Immunology, Physiology
  • Clinical Medicine
  • Life Science & Biotechnology
  • infectious diseases

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.